The standard technique for removal of nonpalpable breast lesions is needle localization breast biopsy. Because traumatic hematomas can often be seen with ultrasound, the authors hypothesized that iatrogenically induced hematomas could be used to guide the excision of nonpalpable lesions using ultrasound.
Conclusion
The results of this pilot study show the effectiveness of hematoma-directed ultrasound-guided breast biopsy for nonpalpable lesions seen by magnetic resonance imaging. This new procedure is potentially more comfortable for the patient because no wire or needle is left in the breast. It is technically faster and easier because ultrasound is used to visualize directly the location of the hematoma at surgery and to confirm lesion removal in the operating room by specimen ultrasound. The hematoma can be placed several days before biopsy, easing scheduling, and without fear of the migration that may occur with needle localization. This method may have ready application to mammographically detected lesions.
Traditionally, nonpalpable breast lesions have been excised using needle localization breast biopsy (NLBB). Magnetic resonance imaging (MRI) of the breast has allowed the appreciation of lesions previously undetected by mammography. Despite the availability of MRI-guided needle localization techniques at ours as well as other institutions, the patient is still subjected to the disadvantages and complica-tions inherent to this method of biopsy. Although NLBB most often results in the successful removal of the targeted lesion in mammographically detected lesions, the miss rate varies from 0% to 22%. [1] [2] [3] [4] The rate is unknown for MRI NLBB, where even thinner wires are used and where the technology is not universally available. Specimen mammography is used to confirm excision of the targeted lesion after NLBB. In contrast, "specimen MRI" is not possible because MRI requires living tissue with a blood supply to demonstrate areas of enhancement of the targeted lesion. Confirmation of removal requires a separate MRI of the remaining breast tissue in the patient on a separate day.
Although NLBB is considered the standard for removal of mammographically detected, nonpalpable breast lesions, disadvantages include the possibility of significant vasovagal reactions, which occur in 10% to 20% of patients, the discomfort of the wire, and the possibility of wire transection or migration. 2, 4 We therefore sought to develop an alternative method that could be used to excise MRI-detected lesions.
Because traumatic hematomas can often be visualized by ultrasound, we hypothesized that iatrogenically induced hematomas could similarly be visualized. Hematomas could then be placed in the breast to identify nonpalpable lesions previously seen only with MRI and could similarly be used to guide their excision and confirm their removal by intraoperative ultrasound.
METHODS

Patients
From August 1999 to September 2000, 20 patients were enrolled in this single-institution trial. Approval was granted by the institutional review board, and patients gave informed consent. Patients included in this study were those who had lesions that were not seen well by mammography or ultrasound but were visualized by MRI alone. Lesions that underwent biopsy had suspicious features, including enhancement by gadolinium, spiculated masses, ring enhancement, or a clumping pattern.
MRI Localization Procedure
Patients were scanned using the MRI technique that uses a pulse sequence called RODEO (rotating delivery of excitation off-resonance). This method produces fat-suppressed images with a high signal-to-noise ratio in three-dimensional acquisition. Patients initially had noncontrast images of the breast in question, followed by an injection of gadolinium and a second MRI. The lesion was identified by increased enhancement on the postcontrast image versus the precontrast image.
Hematoma Injection Procedure
Before MRI scanning, 2 to 5 mL blood was withdrawn for each patient and was left to stand for at least 10 minutes. Air was incorporated into the clotted blood by manual agitation. After the initial images were obtained, a needle, either the 20-gauge E-Z-EM MRI Compatible Breast Lesion Marking System (E-Z-EM Corp., Westbury, NY) or the 14-gauge Daum Coax MRI Needle (Daum Corp., Chicago, IL), was directed into the breast under laser guidance. A second MRI image was obtained to confirm needle placement. Then the blood was injected into the localization needle. Wires were placed through the needle in a few cases.
Intraoperative Ultrasound
The location of the lesion relative to the hematoma was determined from the MRI. A sterilely covered 7.5-MHz linear array transducer (Acoustic Imaging, Dornier Medical Systems, Inc., Kenneshaw, GA) was used to determine the precise hematoma location in the breast. The abnormality was localized in the standard longitudinal and transverse planes. After the incision was made, the transducer was placed inside the incision and the hematoma was again visualized. Dissection was carried straight down toward the chest wall using a "line of sight" technique. 5 This technique ( Fig. 1 ) was adapted from and mimics the use of the gamma probe in sentinel lymph node surgery. The transducer was placed perpendicular to the lesion and parallel to the chest wall to assess the adequacy of the deep margin. Tissue was excised around the hematoma in a block fashion down to the ascertained depth, aiming to achieve a 1-cm margin. Ex vivo ultrasound was performed on the specimen in a basin or glove filled with water. Excision of the targeted lesion was also confirmed by direct visualization of the hematoma by ex vivo ultrasound. Wires, when present, were removed along with the specimen.
Pathology
Intraoperative touch preparation was performed on all six margins (anterior, posterior, medial, lateral, superior, and inferior) as described by our institution and others. 6, 7 Any margins positive by touch prep were reexcised. Subsequently, the margins were inked with six different colors for the six margins. Slides were stained with hematoxylin and eosin and examined for evidence of malignancy. The specimen was serially sectioned at 5-mm intervals. Permanent margins were classified as positive pathologically if tumor cells were present at the inked margin. Hematoxylin and eosin staining was used to confirm hematoma and lesion removal.
RESULTS
Patients
A total of 20 patients with an average age of 53.8 Ϯ 10 years (range 30 -71) gave consent to enroll in this study. Reasons for obtaining MRI in these patients with nonpalpable lesions not seen by mammography were high-risk screening MRI obtained for patients enrolled in a multicenter high-risk MRI protocol; screening for contralateral breast cancer; to determine the extent of a known cancer; to rule out multicentricity; for bloody nipple discharge; and at patient request.
MRI Localization
Breast hematomas were created in 19 of 20 patients using 2 to 5 mL blood per injection site. In the remaining patient, the breast tissue was too dense to allow injection of the blood into the breast tissue, and a wire was placed through the needle used for hematoma injection. Hematomas (Fig.  2) were placed a few hours to 6 days before surgical excision of the lesion. All patients underwent subsequent surgery to the localized areas. In initial cases, wires were placed in addition to hematomas in 13 patients. In several cases, the wire was noted to have migrated distant to the hematoma and lesion.
Ultrasound Localization
Ultrasound was used to localize the hematomas during surgery ( Fig. 3 ) in all 19 patients where hematomas were placed. Ex vivo ultrasound or direct visualization of the hematoma confirmed removal of the hematoma or hematomas in all 19. Hematoma-Directed US-Guided Breast Biopsy Pathology Eight (40%) of the MRI-detected lesions were malignant, with an average tumor size of 12 Ϯ 6 mm (range 4 -25). The remaining 12 lesions (60%) comprised papillomas, fibrous mastopathy, sclerosing adenosis, radial scar, fibroadenoma, and areas of atypical ductal hyperplasia. The average size of the benign lesions was 12 Ϯ 4 mm (range 5-15). More than one hematoma was placed in the breast to outline the extent of disease in 14 patients. As seen in Figure 4 , hematomas were placed superior and inferior to the lesion to outline and guide surgical resection. In three patients, more than one hematoma was placed to localize more than one lesion. The hematoma that was visualized by MRI, ultrasound, and then grossly ( Fig. 5 ) in many cases could also be visualized microscopically to confirm lesion removal (Fig. 6 ). The average closest margin was 3 Ϯ 2 mm (range 0 -7).
Complications
Skin necrosis developed in one patient. In another patient, an immediate postoperative hematoma developed that required evacuation. Two patients had margins that were either positive or less than 1 mm and subsequently had completion mastectomies.
DISCUSSION
The results of this pilot study show the effectiveness of hematoma localization for excisional breast biopsies in cases requiring some type of image-guided localization, in particular MRI-visualized lesions. With the increasing availability of MRI for the breast, a surgeon is often faced with a dilemma on how best to perform excisional biopsy on these lesions when they cannot be visualized by any other imaging method. Our institution and many others have shown success using ultrasound in the operating room to excise nonpalpable lesions. 1,8 -14 It seems a natural extension to apply this practice to lesions that are seen only with MRI but can be targeted for ultrasound by using semiclotted blood. Our intraoperative localization rate of 100% (19/19) has shown this method to be successful in the hands of surgeons experienced in the use of ultrasound.
This technique of hematoma injection to mark breast lesions for removal also addresses many of the problems related to the standard practice for biopsy of nonpalpable lesions. It also avoids the discomfort of long-term needle placement in the breast. The actual MRI and localization procedure takes only about 45 minutes to 1 hour to perform. The breast lesion may be localized several weeks before surgical excision, thus lessening the need to coordinate the localization procedure in radiology with the surgical excision in the operating room. In this study, the longest time from hematoma injection to surgical excision was 6 days. However, we have performed ultrasound-guided excisional breast biopsy using stereotactically induced hematomas to guide the dissection up to 3 weeks after the needle biopsy. The length of time between localization and excision would be limited by the amount of time it takes for the injected hematoma to reabsorb into the surrounding tissues. This allows a great deal of flexibility in scheduling, because the lesion may be localized at any time during the week before surgery. Problems such as wire migration and transection, which may occur with standard NLBB, are not an issue with hematoma-directed breast biopsy. In the initial patients, in whom a needle was placed in addition to the hematoma, we found that the hematoma more accurately represented the location of the lesion in the breast. The wire/needle had often migrated in the breast before excision.
This article represents the first report of a new technique of hematoma-directed ultrasound-guided excisional breast biopsy. Currently there is no injectable agent approved by the U.S. Food & Drug Administration (FDA) that can be imaged by ultrasound. Unlike other techniques under development, this procedure does not require FDA approval because it uses the patient's own blood. This technique can be used not only to localize a MRI-detected lesion, but also to outline the targeted lesion for complete excision and to obtain margins. Although this technique can be readily applied to nonpalpable lesions (MRI or mammographic), it shifts the onus of localization from the radiologist to the About two years ago I was talking to Dr. Klimberg about how she finds the lesion in the breast that has been biopsied by mammotome or by stereotactic biopsy and all the microcalcifications have been removed.
A mammogram won't show any microcalcifications. How do you find the lesion? She said that's easy. You just put your ultrasound on the breast, and the ultrasound shows the hematoma from the biopsy. You take the hematoma out, and that's where that mammotome biopsy was.
That's a great idea, and as an audience, we should all remember that technique. We use it with some regularity when we can't find the lesion by mammogram after a mammotome biopsy. Ultrasound the breast, find the hematoma, take the hematoma out, that's where the lesion was.
I have to wonder if MRI localization, however, isn't a technique before its time. Most of us don't use MRI -well, retract that. I don't use MRI very often. I find that high-resolution mammography, compression techniques, and magnification techniques suffice, particularly if the lesions are 1cm in size, the average size of both benign and malignant lesions in this study.
MRI's are particularly useful to outline the extent of DCIS, and to outline recurrent lesions after lumpectomy and radiation therapy, but we have not applied MRI routinely across the board to patients for screening purposes as was mentioned here.
Again, we have to be a little bit careful medical-legally. I have patients calling me to find out if they can obtain MRI's at our institution, which they can, but they are almost demanding them. I think that one of the first things that you need to do, Suzanne, in your group, particularly your multiinstitutional group that is studying MRI's, is to convince us, not the public-I think you can convince the public very quickly that they need MRI's. I think you need to convince the rest of us that your MRI is in fact better and is cost effective. Remember, this study requires two MRI's, and it requires probably a reasonably expensive localization technique using your laser tools.
I think your idea of injecting the patients own blood to use for ultrasound localization is an excellent idea and much less expensive than needle localization. This does not, however, require an MRI, only an ultrasound.
In your multi-institutional MRI trial, what do you plan to use the data for? Because you are going to find, almost by definition, that it MRI is useful, or else you wouldn't do the trial. So you are going to tell us all at some point in time how great MRI is for breast lesions, and it's going to get in the lay paper, and it's going to create a problem for those of us who don't have MRI's for breasts, don't use the technique and may feel compelled to either get an MRI or get somebody that has one. Let us know why MRI's are so good and why we must switch our techniques from the ones that we use currently. It should take a lot of convincing to switch from a rather simple mammographic technique to your expensive MRI technique before the public is lead to believe that MRI is a significantly better test.
Thank you very much. DR. F. CHARLES BRUNICARDI (Houston, Texas): I'd like to thank Dr. Klimberg and her co-authors for the opportunity to discuss this exciting paper and for e-mailing me the manuscript well in advance of the meeting.
Dr. Klimberg and her colleagues are to be congratulated on yet another potential advance in the diagnosis and treatment of breast lesions. With studies such as this one, Dr. Klimberg has established a reputation as one of the nation's leading breast surgeons.
This study represents a successful feasibility clinical trial with IRB approval and informed consent, so important in this area of charge clinical trials.
Twenty patients, mostly high risk with lesions not seen on mammogram or ultrasound, were enrolled following a suspicious breast MRI. What I found remarkable is that 40% of their patients had cancer and that their mammograms were not diagnostic. So like Dr. Copeland, my first question is are you advocating the use of rodeo MRI for high-risk patients?
In the manuscript you discuss the use of touch prep and the use of re-excision of margins during the diagnostic biopsy. So my next question: are you recommending that the general surgeons strive to achieve negative margins during the initial diagnostic biopsy?
The two patients who had positive margins on the final pathology had subsequent completion mastectomies. Were these patients offered breast conservation with segmental mastectomy?
I would like to thank the Association for the privilege to discuss this exciting paper.
DR. JOHN I. HOLLENBECK (Charlotte, North Carolina): I rise to congratulate Dr. Klimberg and her colleagues for once again thinking outside the box a little bit. I think she is pretty well known for coming up with some pretty good ideas that take a little while for some of us to catch onto.
Dr. Copeland asked the same question that I'm asking. Since a lot of us don't use MRI, how can we use this on a mammogram patient?
Secondly, I think it is very important to note the last statement that Suzanne made is that the surgeon has got to become competent in the use of ultrasound and breast disease. Now we are perfectly aware most fellowships in breast disease encompass this, but it is not always encompassed in general surgery training to the degree I think it ought to be. I think that is a very important message to take home from this. Thank you. DR. MARCIA MOORE (Charlottesville, Virginia): I just want to congratulate Dr. Klimberg on a great paper and ask one quick question of her.
When the hematoma is placed, I worry about the possibility that the size of the breast tumor assessment may be changed by the positioning of the hematoma next to or within the tumor. Do you have any comments about whether a lesion that is 4mm, 8mm, or 12mm can impact greatly on the recommendations that the patient has for subsequent therapy? And I'd like to know if that hematoma placement could indeed compromise the pathologic evaluation of the size of the tumor.
Thank With regard to the question about applying this technique to mammogram. We have seen lesions on mammogram in our clinics, and we have drawn blood from the patient. Using the mammogram to guide the area, we inject the blood into the breast tissue, use the ultrasound to look for the hematoma within the breast, send the patient back down, and then have another mammogram done. If it looks like the hematoma is where the lesion was on the mammogram, then we can use that to guide the dissection at surgery.
We have also theorized that you could apply this technique possibly to images seen with PET scanning and also scintimammography, although we have not done that.
Regarding the question about the usefulness of MRI, most of these patients were on a high-risk MRI protocol study, and they have a strong family history of breast cancer, with a risk assessment of greater than 30% lifetime risk for breast cancer. Studies have shown that patients that have a strong family history of breast cancer and who undergo these MRI studies will find an additional 3 to 4% of breast cancers. And, surprisingly, we did find a significant number of breast cancers in our study.
Talking about the use of margins, with the two patients that did have positive margins, we were initially trying to obtain negative margins and just have a segmental mastectomy. However, we were not able to do that, so these two patients did go on to have completion mastectomies. As Dr. Klimberg described, the hematoma is outlining the lesion. We can use the ultrasound and go about a 1cm distance away from the hematoma to, hopefully, obtain negative margins.
With regard to the question about the blood being clotted or semiclotted, the blood is drawn from the patient prior to the procedure, the MRI. Sometimes it is drawn through the I.V. Occasionally we have to stick the patient in the arm. The blood is left in a syringe, and air is drawn into the blood itself. It is agitated and left set about 10 minutes. It is very viscous and semi-clotted but not fully clotted when it is injected.
In conclusion, I would like to state that this procedure is very simple to perform with the availability of both MRI and ultrasound. The technique could be adapted to lesions seen also by mammography, PET scanning, and scintimammography. I think it would be very useful for the mammographic lesions that are not seen with ultrasound. However, the technique does require a surgeon who is experienced and comfortable with breast ultrasound.
Once again, I would like to thank the Society, Dr. Aust, and Dr. Townsend for the privilege of responding.
Thank you.
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